Cargando…

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets

Biliary tract cancers (BTCs) currently have no approved targeted therapies. Although genomic profiling of primary BTCs has identified multiple potential drug targets, accurate models are needed for their evaluation. Genomic profiling of 22 BTC cell lines revealed they harbor similar mutational signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lau, David K., Mouradov, Dmitri, Wasenang, Wiphawan, Luk, Ian Y., Scott, Cameron M., Williams, David S., Yeung, Yvonne H., Limpaiboon, Temduang, Iatropoulos, George F., Jenkins, Laura J., Reehorst, Camilla M., Chionh, Fiona, Nikfarjam, Mehrdad, Croagh, Daniel, Dhillon, Amardeep S., Weickhardt, Andrew J., Muramatsu, Toshihide, Saito, Yoshimasa, Tebbutt, Niall C., Sieber, Oliver M., Mariadason, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889747/ https://www.ncbi.nlm.nih.gov/pubmed/31731200 http://dx.doi.org/10.1016/j.isci.2019.10.044

Ejemplares similares

Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases
por: Wasenang, Wiphawan, et al.
Publicado: (2019)

K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines
por: Yeung, Yvonne, et al.
Publicado: (2017)

DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis
por: Tögel, Lars, et al.
Publicado: (2018)

Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis
por: Tögel, Lars, et al.
Publicado: (2023)

Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death
por: Jenkins, Laura J., et al.
Publicado: (2023)

ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer
por: Luk, Ian Y., et al.
Publicado: (2018)

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
por: Lau, David K., et al.
Publicado: (2018)

The relationship between P16(INK4A) and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand
por: Poosari, Arisara, et al.
Publicado: (2022)

Biomarker to distinguish hepatocellular carcinoma from cholangiocarcinoma by serum a disintegrin and metalloprotease 12
por: Daduang, Jureerut, et al.
Publicado: (2011)

Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression
por: Luk, Ian Y., et al.
Publicado: (2022)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

Implications of Epithelial–Mesenchymal Plasticity for Heterogeneity in Colorectal Cancer
por: Pereira, Lloyd, et al.
Publicado: (2015)

The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines
por: Choodetwattana, Phatchareeporn, et al.
Publicado: (2019)

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
por: Weickhardt, A J, et al.
Publicado: (2015)

Green synthesized apigenin conjugated gold nanoparticles inhibit cholangiocarcinoma cell activity and endothelial cell angiogenesis in vitro
por: Ngernyuang, Nipaporn, et al.
Publicado: (2022)

The development of simultaneous measurement of viral load and physical status for human papillomavirus 16 and 18 co-infection using multiplex quantitative polymerase chain reaction
por: Prasongdee, Prinya, et al.
Publicado: (2018)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

A novel TFF2 splice variant (ΔEX2TFF2) correlates with longer overall survival time in cholangiocarcinoma
por: KAMLUA, SURASEE, et al.
Publicado: (2011)

Serum Cystatin C as a Potential Marker for Glomerular Filtration Rate in Patients with Cholangiocarcinoma
por: Ciin, Mang Ngaih, et al.
Publicado: (2020)

Interleukin 25 (IL-25) expression in cholangiocarcinoma
por: Kaewsarabhumi, Supakit, et al.
Publicado: (2020)

Serum Levels of Cytokine-Induced Apoptosis Inhibitor 1 (CIAPIN1) as a Potential Prognostic Biomarker of Cholangiocarcinoma
por: Truong, Son Dinh An, et al.
Publicado: (2021)

Prediction of CIAPIN1 (Cytokine-Induced Apoptosis Inhibitor 1) Signaling Pathway and Its Role in Cholangiocarcinoma Metastasis
por: Truong, Son Dinh An, et al.
Publicado: (2022)

Establishment and Long-Term Culture of Organoids Derived from Human Biliary Tract Carcinoma
por: Saito, Yoshimasa, et al.
Publicado: (2020)

Serum coiled-coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma
por: Chanakankun, Ravinnipa, et al.
Publicado: (2020)

Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells
por: Diesch, Jeannine, et al.
Publicado: (2014)

Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma
por: Tummanatsakun, Doungdean, et al.
Publicado: (2019)

MACROD2 deletions cause impaired PARP1 activity and chromosome instability in colorectal cancer
por: Sakthianandeswaren, Anuratha, et al.
Publicado: (2018)

Gallic acid conjugated with gold nanoparticles: antibacterial activity and mechanism of action on foodborne pathogens
por: Rattanata, Narintorn, et al.
Publicado: (2016)

Apoptosis-Inducing Factor, Mitochondrion-Associated 3 (AIFM3) Protein Level in the Sera as a Prognostic Marker of Cholangiocarcinoma Patients
por: Chua-on, Daraporn, et al.
Publicado: (2020)

Pylorus Preserving Pancreaticoduodenectomy
por: Nikfarjam, Mehrdad
Publicado: (2010)

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*
por: Price, Timothy J, et al.
Publicado: (2013)

Reprogrammed Lipid Metabolism and the Lipid-Associated Hallmarks of Colorectal Cancer
por: Salita, Timothy, et al.
Publicado: (2022)

Metastatic clear cell renal cell carcinoma demonstrating intense uptake on (68)Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature
por: Nadebaum, David P., et al.
Publicado: (2018)

Embryonal Sarcoma of the Liver in an Adult Patient
por: Lightfoot, Nicole, et al.
Publicado: (2012)

Cluster microRNAs miR‐194 and miR‐215 suppress the tumorigenicity of intestinal tumor organoids
por: Nakaoka, Toshiaki, et al.
Publicado: (2017)

Genomic Signature of Oral Squamous Cell Carcinomas from Non-Smoking Non-Drinking Patients
por: Koo, Kendrick, et al.
Publicado: (2021)

Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer
por: Sharafi, Golnaz, et al.
Publicado: (2019)

Prospective multicentre randomised controlled trial of the effect of Braun Enteroenterostomy in the Reconstruction after Pancreaticoduodenectomy on delayed gastric emptying (DGE): protocol for the BERP study
por: Gupta, Saksham, et al.
Publicado: (2022)

Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy
por: Lau, David K., et al.
Publicado: (2019)

A Biobank of Colorectal Cancer Patient-Derived Xenografts
por: Abdirahman, Suad M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o7d072q224duh4igo64sp9i31p